Back to Search
Start Over
Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies.
- Source :
-
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2023 Mar; Vol. 57 (2), pp. 396-398. - Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 2168-4804
- Volume :
- 57
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Therapeutic innovation & regulatory science
- Accession number :
- 36472778
- Full Text :
- https://doi.org/10.1007/s43441-022-00487-w